BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASEMODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY.

Authors :: Tillett, W.
Merola, J. F.
Tanaka, Y.
Favalli, E. G.
Mcgonagle, D.
Walsh, J. A.
Thaçi, D.
Ink, B.
Bajracharya, R.
Taieb, V.
Ritchlin, C. T.
Source :: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p1130-1130, 2/3p
Publication Year :: 2023

Full Text Access

Tools